Industry Press Releases

Takara Bio Selects AGC Biologics to Manufacture Plasmid DNA Intermediate for COVID-19 Vaccination (SARS-CoV-2)

Friday, May 22, 2020

AGC Biologics , an international contract development and manufacturing company (CDMO) for biopharmaceuticals, has announced its collaboration with Takara Bio , who will work together to fight COVID-19 by working together on a prophylactic Develop a DNA vaccine, with AGC Biologics producing the intermediate plasmid DNA for vaccination.

"We are doing hard work in our fight against COVID-19," said Koichi Nakao , CEO of Takara Bio . "We are grateful for the support of AGC Biologics. This collaboration enables us to develop this vaccine faster and more safely. "

The vaccine will be developed based on the expertise of the University of Osaka and AnGes, Inc. in the development of plasmid DNA products.

"AGC Biologics is looking forward to working with Takara Bio on a project that plays a role for an incredible number of people," said Mark Womack , CBO of AGC Biologics. "Our company is looking forward to working successfully with Takara Bio against this worldwide To fight threat. "

AGC Biologics, which has manufacturing facilities in Asia, Europe and the United States, has decades of experience as a contract development, manufacturing and supplying company for the commercial market with PDMA, EMA and FDA approvals. AGC Biologics has a proven track record of 10 years in the commercial production of plasmids and a highly customizable approach to any plasmid requirement to meet the rapidly increasing demand for pDNA.

About Takara Bio :
Takara Bio Inc. started as a division of biomedical Takara Shuzo Co., Ltd. (Today Takara Holding Inc.). Based on the company's mission - to contribute to human health through the development of revolutionary biotechnology and gene therapy - Takara Bio focuseson two main business areas in which the company is using its core biotechnology and spurring it towards broader expansion: the business area of the bioindustry, which forms the basis for stable yields through the provision of research reagents, scientific instruments and various contractual services for researchers in the field of life sciences at universities and in companies around the world; and the business area of  gene therapy that the company sees as the basis for future growth through the development and commercialization of gene therapies for cancer and other diseases. With CGCP I & II (Center for Gene and Cell Processing) Takara Bio through two large-scale GMP / GCTP-compatible facilities that develop and manufacture products such as regenerative medicine and biopharmaceuticals, and that work on the manufacture of this preventive DNA vaccine.

About AGC Biologics: AGC Biologics is a leading contract development and manufacturing company (CDMO) that is increasingly committed to providing its customers and partners with the highest possible standard of service. The company currently has more than 1000 employees worldwide. AGC Biologics' extensive network spans three continents, with cGMP-compliant facilities in Seattle , Washington, Copenhagen, Denmark, Heidelberg, Germany, and Chiba , Japan .

AGC Biologics has in-depth industry know-how and unique tailor-made services for the enhanced and cGMP production of protein-based therapeutics from preclinical to commercial production for mammalian and microbial cells. Our integrated service offering includes cell line development, bioprocess development, formulation, analytical testing, development and conjugation of antibody drugs, cell banks and cell storage and protein expression, including our own CHEF1® Expression System for mammalian cells.

More information is available at .



Other Press Releases